Anup Agarwal
Overview
Explore the profile of Anup Agarwal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agrawal S, Alhaddad Z, Nabia S, Rehman O, Kiyani M, Kumar A, et al.
J Card Fail
. 2024 Sep;
PMID: 39332476
Background: The American Heart Association/American College of Cardiology/Heart Failure Society of America recently added sodium-glucose cotransporter-2 inhibitors in addition to renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists to form...
2.
Kole A, Agarwal A, Seth B, Sandhu S, Ghali B, Arya P, et al.
Natl Med J India
. 2024 May;
36(3):163-166.
PMID: 38692613
Background Cardiovascular diseases, including heart failure (HF), are leading causes of death and disability in India. However, most studies in India only include urban populations or rural regions with improved...
3.
4.
Agarwal A, Leviter J, Mannarino C, Levit O, Johnston L, Auerbach M
BMJ Simul Technol Enhanc Learn
. 2022 May;
1(1):5-11.
PMID: 35517842
Objective: To compare the efficacy of a three-dimensional (3D) haptic interface to a two-dimensional (2D) mouse interface for a screen-based simulation (SBS) neonatal intubation (NI) training intervention. Primary hypothesis: a...
5.
Troxel A, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al.
JAMA Netw Open
. 2022 Jan;
5(1):e2147331.
PMID: 35076699
Importance: COVID-19 convalescent plasma (CCP) is a potentially beneficial treatment for COVID-19 that requires rigorous testing. Objective: To compile individual patient data from randomized clinical trials of CCP and to...
6.
Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, et al.
JAMA Netw Open
. 2022 Jan;
5(1):e2147375.
PMID: 35076698
Importance: Identifying which patients with COVID-19 are likely to benefit from COVID-19 convalescent plasma (CCP) treatment may have a large public health impact. Objective: To develop an index for predicting...
7.
Mammen J, Kumar S, Thomas L, Kumar G, Zachariah A, Jeyaseelan L, et al.
BMJ Open
. 2021 Oct;
11(10):e050571.
PMID: 34607865
Objective: Large data on the clinical characteristics and outcome of COVID-19 in the Indian population are scarce. We analysed the factors associated with mortality in a cohort of moderately and...
8.
Agrawal S, Agarwal A, Jain Y
Indian J Med Ethics
. 2021 Jul;
VI(3):1-7.
PMID: 34287194
Convalescent plasma therapy emerged as an early experimental therapy for the treatment of Covid-19. However, despite limited data regarding its safety and efficacy, the therapy was extensively publicised by multiple...
9.
Khaire N, Jindal N, Yaddanapudi L, Sachdev S, Hans R, Sachdeva N, et al.
Indian J Med Res
. 2021 Apr;
153(1 & 2):64-85.
PMID: 33818467
Convalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19...
10.
Mukherjee A, Anand T, Agarwal A, Singh H, Chatterjee P, Narayan J, et al.
Epidemiol Infect
. 2021 Mar;
149:e82.
PMID: 33766185
The current investigation was conducted with the objective to develop an epidemiological case definition of possible severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) re-infection and assess its magnitude in India. The epidemiological...